Predictive circulating biomarkers of the response to anti-PD-1 immunotherapy in advanced HER2 negative breast cancer

Abstract

	•CD39+ Tregs in peripheral blood are associated with poor response to anti-PD-1 immunotherapy in advanced breast cancer.
	•Higher frequencies of CCR2+ monocyte-derived dendritic cells correlate with better immunotherapy outcomes.
	•A predictive model based on CD39+ Tregs and monocyte-derived dendritic cells effectively distinguishes patient progression-free survival.
	•Peripheral blood biomarkers offer a non-invasive approach to guide immunotherapy choices.

Keywords

breast cancer / CyTOF / immunotherapy / PD-1 / peripheral blood mononuclear cell / predictive biomarkers / systemic immunity

References

[1] Cortes J, Rugo HS, Cescon DW, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022;387(3):217-226.

[2] Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108-2121.

[3] Wei Y, Du Q, Jiang X, et al. Efficacy and safety of combination immunotherapy for malignant solid tumors: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2019;138:178-189.

[4] Medina A, Carballo J, González-Marcano E, Blanca I, Convit AF. Breast cancer immunotherapy: realities and advances. Cancer Innovation. 2024;3(5):e140.

[5] Emens LA, Adams S, Barrios CH, et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: iMpassion130 final overall survival analysis. Ann Oncol. 2021;32(8):983-993.

[6] Holder AM, Dedeilia A, Sierra-Davidson K, et al. Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours. Nat Rev Cancer. 2024;24(7):498-512.

[7] Zeng C, Xu C, Wei Y, Ma F, Wang Y. Training and experimental validation a novel anoikis-and epithelial-mesenchymal transition-related signature for evaluating prognosis and predicting immunotherapy efficacy in gastric cancer. J Cancer. 2025;16(4):1078-1100.

[8] Spitzer MH, Carmi Y, Reticker-Flynn NE, et al. Systemic immunity is required for effective cancer immunotherapy. Cell. 2017;168(3):487-502.e415.

[9] Hiam-Galvez KJ, Allen BM, Spitzer MH. Systemic immunity in cancer. Nat Rev Cancer. 2021;21(6):345-359.

[10] Tselikas L, Dardenne A, de Baere T, et al. Feasibility, safety and efficacy of human intra-tumoral immuno-therapy. Gustave Roussy’s initial experience with its first 100 patients. Eur J Cancer. 2022;172:1-12.

[11] Gao M, Wu X, Jiao X, et al. Prognostic and predictive value of angiogenesis-associated serum proteins for immunotherapy in esophageal cancer. J Immunother Cancer. 2024;12(2):e006616.

[12] Parra ER, Zhang J, Duose DY, et al. Multi-omics analysis reveals immune features associated with immunotherapy benefit in patients with squamous cell lung cancer from phase III Lung-MAP S1400I trial. Clin Cancer Res. 2024;30(8):1655-1668.

[13] Krieg C, Nowicka M, Guglietta S, et al. High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. Nat Med. 2018;24(2):144-153.

[14] Dyikanov D, Zaitsev A, Vasileva T, et al. Comprehensive peripheral blood immunoprofiling reveals five immunotypes with immunotherapy response characteristics in patients with cancer. Cancer Cell. 2024;42(5):759-779.e712.

[15] Anagnostou V, Ho C, Nicholas G, et al. ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results. Nat Med. 2023;29(10):2559-2569.

[16] Powles T, Chang Y-H, Yamamoto Y, et al. Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial. Nat Med. 2024;30(9):2508-2516.

[17] Mo H, Yu Y, Sun X, et al. Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial. Nat Med. 2024;30(9):2528-2539.

[18] Hao Y, Hao S, Andersen-Nissen E, et al. Integrated analysis of multimodal single-cell data. Cell. 2021;184(13):3573-3587.e3529.

[19] Lozano AX, Chaudhuri AA, Nene A, et al. T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma. Nat Med. 2022;28(2):353-362.

[20] Kluger HM, Tawbi HA, Ascierto ML, et al. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC immunotherapy resistance taskforce. J Immunother Cancer. 2020;8(1):e000398.

[21] Kluger H, Barrett JC, Gainor JF, et al. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors. J Immunother Cancer. 2023;11(3):e005921.

[22] Vignali PDA, DePeaux K, Watson MJ, et al. Hypoxia drives CD39-dependent suppressor function in exhausted T cells to limit antitumor immunity. Nat Immunol. 2023;24(2):267-279.

[23] Steele MM, Jaiswal A, Delclaux I, et al. T cell egress via lymphatic vessels is tuned by antigen encounter and limits tumor control. Nat Immunol. 2023;24(4):664-675.

[24] Moesta AK, Li XY, Smyth MJ. Targeting CD39 in cancer. Nat Rev Immunol. 2020;20(12):739-755.

[25] Deaglio S, Dwyer KM, Gao W, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007;204(6):1257-1265.

[26] Sade-Feldman M, Yizhak K, Bjorgaard SL, et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell. 2018;175(4):998-1013.e1020.

[27] Retseck J, Nasr A, Lin Y, et al. Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma. J Transl Med. 2018;16(1):184.

[28] Mathewson ND, Ashenberg O, Tirosh I, et al. Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. Cell. 2021;184(5):1281-1298.e1226.

[29] Sun Y, Wu L, Zhong Y, et al. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. Cell. 2021;184(2):404-421.e416.

[30] Alvarez Calderon F, Kang BH, Kyrysyuk O, et al. Targeting of the CD161 inhibitory receptor enhances T-cell–mediated immunity against hematological malignancies. Blood. 2024;143(12):1124-1138.

[31] Di W, Fan W, Wu F, et al. Clinical characterization and immunosuppressive regulation of CD161 (KLRB1) in glioma through 916 samples. Cancer Sci. 2021;113(2):756-769.

[32] Heras-Murillo I, Adán-Barrientos I, Galán M, Wculek SK, Sancho D. Dendritic cells as orchestrators of anticancer immunity and immunotherapy. Nat Rev Clin Oncol. 2024;21(4):257-277.

[33] Nutt SL, Chopin M. Transcriptional networks driving dendritic cell differentiation and function. Immunity. 2020;52(6):942-956.

[34] Kuhn S, Yang J, Ronchese F. Monocyte-derived dendritic cells are essential for CD8+ T cell activation and antitumor responses after local immunotherapy. Front Immunol. 2015;6:584.

[35] Schetters STT, Rodriguez E, Kruijssen LJW, et al. Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy. J Immunother Cancer. 2020;8(2):e000588.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.